Clinical trials
catalyst calendar across sponsors →Studies where ATOS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional · 2 observational · 2 with posted results
Held by 4 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC, MILLENNIUM MANAGEMENT LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 13.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast CancerNCT05607004PK Cohort - (Z)-endoxifen steady-state plasma concentrationsNon-randomized · Open-label · Treatment | Phase 2 | Active, not recruiting | Drug: (Z)-endoxifen, goserelin | Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer | 87 | Nov 2026 | ≤ 103 d | 2026-07-08 |
| Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast DensityNCT05068388Change of mammographic density area (cm2) assessed by iCAD® softwareRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Z-Endoxifen, Placebo | Breast Density | 240 | 2024-06-14actual | — | 2026-05-20 |
| AT-301 Nasal Spray in Healthy AdultsNCT04519788cardiac, pulmonary and hemodynamic parameters using 12-lead ECGRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: AT-301B, AT-301A | Healthy | 32 | 2020-12-08actual | — | 2021-01-19 |
| A Pre-Surgical PK Study of IM and Intraductally Delivered FulvestrantNCT02540330results2022-04-05Safety and Tolerability of Two Delivery MethodsNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Business decision (See Detailed Description) | Drug: Fulvestrant | Female Breast Carcinoma, Female Ductal Carcinoma In Situ | 3 | 2020-08-13actual | — | 2024-04-03 |
| Topical Endoxifen in WomenNCT04616430results2021-06-18Change in Mammographic Breast Density At Study ExitRandomized · Triple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Topical endoxifen, Placebo | Mammographic Breast Density | 90 | 2018-09-10actual | — | 2021-07-12 |
| A Trial of the ForeCYTE Breast Aspirator for Cytological Testing of Nipple Aspirate Fluid in Women 30-55 Years OldNCT02539615NAF cytological classification(s), according to the modified King Classification.Non-randomized · Open-label · Screening | Phase 3 | Withdrawn | Device: ForeCYTE Breast Aspirator | Breast Cancer, Preneoplastic Conditions, BRCA | 0 | Dec 2015 | — | 2016-01-25 |
| ForeCYTE Breast Aspirator for Sample Collection and Cytological Testing of Nipple Aspirate FluidNCT02218385observationalSpecimen Acceptance Rate | — | Completed | Device: ForeCYTE Breast Aspirator | Breast Neoplasms | 52 | Aug 2014actual | — | 2016-10-19 |
| The Breast Duct: Pilot Study of Genomic Sequencing of Exfoliated Ductal Cells Obtained Through Endoscopy and LavageNCT02121873observationalIdentify early epithelial somatic mutations/indels in precancerous breast ducts by comparing genetic DNA sequences from cells obtained from venous blood and ductal lavage | — | Completed | Device: Nipple aspirator, Ductal lavage microcatheter, Blood draw | Breast Cancer, Preneoplastic Conditions, Ductal Carcinoma in Situ | 6 | Sep 2011actual | — | 2023-07-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19